Anti-CD22 CAR-T (Tianjin First Center Hospital)(Anti-CD22 CAR-T (Tianjin First Center Hospital)) - 药物靶点：CD22_在研适应症：急性淋巴细胞白血病_专利_临床

概要

基本信息

药物类型

自体CAR-T

别名-

靶点

CD22

作用机制

CD22抑制剂(CD22抑制剂)

治疗领域

肿瘤免疫系统疾病血液及淋巴系统疾病

在研适应症

急性淋巴细胞白血病

非在研适应症-

原研机构

Tianjin First Center Hospital

在研机构

Tianjin First Center Hospital

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

2

项与 Anti-CD22 CAR-T (Tianjin First Center Hospital) 相关的临床试验

ChiCTR1800019298 / RecruitingIIT

CD22 CAR T–cell therapy for relapse or refractory B-cell Lymphoma or acute B lymphocytic leukemia

开始日期2018-11-01

申办/合作机构-

ChiCTR-ONN-16009862 / RecruitingIIT

CD19 CAR T–cell therapy for relapse or refractory B-cell Lymphoma and acute B lymphocytic leukemia

开始日期2016-11-01

申办/合作机构-

100 项与 Anti-CD22 CAR-T (Tianjin First Center Hospital) 相关的临床结果

登录后查看更多信息

100 项与 Anti-CD22 CAR-T (Tianjin First Center Hospital) 相关的转化医学

登录后查看更多信息

100 项与 Anti-CD22 CAR-T (Tianjin First Center Hospital) 相关的专利（医药）

登录后查看更多信息

1

项与 Anti-CD22 CAR-T (Tianjin First Center Hospital) 相关的文献（医药）

2023-09-19·Leukemia & Lymphoma

Differences in efficacy and safety among CAR-Ts anti-CD19/CD22, anti-CD19, and anti-CD22, in adult patients with relapse/refractory B-cell acute lymphoblastic leukemia: a meta-analysis and systematic review

Review

作者: Becerril-Rico, Jared ; Ortiz-Sánchez, Elizabeth ; Delgado-Montes, Yerenia A

Relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) is a challenging disease with low rates of remission and survival in adult patients. Anti-CD19 Chimeric Antigen Receptor T-cells (CAR-Ts) therapies have been approved for these patients. Dual-target CAR-Ts against CD19 and CD22 have recently been developed to improve the efficacy of the single-target therapy; however, extent of the improvement using this dual-target therapy has yet to be determined. We performed a meta-analysis of the outcome and safety of CAR-Ts, comparing anti-CD19 vs anti-CD22 vs dual-target anti-CD19/CD22 CAR-Ts, to elucidate the differences and limitations of these therapies in adult patients with R/R B-ALL. Although the limitations of our study derived from heterogeneity in the included publications, our results suggest that anti-CD19/CD22 CAR-Ts generate lower incidence of relapse and neurotoxicity, but similar results were obtained regarding complete remission, minimal residual disease, overall survival, and cytokine release syndrome compared with single-target anti-CD19 and anti-CD22 CAR-Ts.

100 项与 Anti-CD22 CAR-T (Tianjin First Center Hospital) 相关的药物交易

登录后查看更多信息